Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content
Sylvana blog 1

Colorectal cancer (CRC) is the third most common cancer in the world with 150,000 new cases each year. At initial diagnosis, 20% of patients have distant metastasis, thus the cancer has spread to other parts and organs of the body and is not confined to the colon or rectum. 25% to 30% of patients with early stage disease will develop metastasis consequently. The subsequent duration of life for metastatic untreated patients is a heart-aching number accounting for a maximum of 9 months.

Currently, using combination therapy approaches, overall survival lengths has been extended to 20 months. The standard of care for metastatic CRC is surgery followed by chemotherapy. There are several approved chemotherapeutic drugs, one of which is the administration of 5-fluorouracil (5FU) with oxaliplatin given mainly through the course of 12 month,s biweekly. The response rate for this treatment is 29%.

Therapy based upon the biology of an individual’s tumour rather than established histopathologic and anatomic classification is an approach that promises to optimise the use of existing therapies. Gene expression analysis offers the potential to measure genome-wide activity which can be used to predict response to current treatments. My project aims at creating a predictive model that can determine which patients are sensitive or resistant to different chemotherapeutic treatment.

In the future, if we, or any other research group, succeeded in reaching this purpose, we would be able to identify the 71% of patients who may not benefit from chemotherapy. I think modifying the standard of care for CRC will have impactful results on the life of patients and this is our ultimate goal as cancer researchers.

Blog posts

A gut feeling for cancer treatment

The bacteria that inhabit our gut – the gut microbiome - could have profound impact on our health. The species that live in our guts influence the development of neurodegenerative disease (Alzheimer disease, Parkinson’s disease), epilepsy, autoimmune disease, and cancer.4 They may also be helping shape whether our treatments work.

In the right place …

When people don’t know they’ve supported your work, how do you say ‘Thank you!’? Obviously, you can hold a celebration event. Publicise widely, invite people in. Sweeten the offer with nibbles?

Two worlds collide – dark and light blue worlds meet.

In my spare time, I work for the RAF Air Cadets as a volunteer instructor. It’s challenging, rewarding and fun, but it’s not often that the light blue of the RAF is seen on the Old Road Campus.

Chocolate is not just for eating – it can be inspiring

Engaging people with our science is a job for all. We have some amazing people in Oncology and some of them are not afraid to get out of their comfort zone. In this blog, Roxy Peerless, from our finance group, shows once again that public engagement is not just for scientists.

Oncology Open Day

On Wednesday the 3rd of April 2019, myself and 30 other students, from Sir William Borlase’s Grammar School, attended the Oxford University Oncology Open Day at the Cancer Research Centre, Oxford.